Summer Street says more optimistic on MannKind approval

Summer Street says it is more optimistic that the current trials of MannKind's inhalable insulin Afrezza could lead to FDA approval. The firm notes the product is completing two phase III trials and that it has been skeptical of approval in the past. Summer Street does not have an official rating on shares of MannKind, which are up 22c to $5.38 in early trading.

http://www.theflyonthewall.com/permalinks/entry.php/MNKDid1835091/MNKD-Summer-Street-says-more-optimistic-on-MannKind-approval